Search - tctmd.com

Displaying 21 - 38 of 38

Sort: Relevancy | Date

News Industry News

Good Samaritan Hospital Offers an Alternative to Long-Term Warfarin Medication for Atrial Fibrillation with Newly Approved Watchman™ LAAC Implant

May 18, 2015

News Industry News

University of Michigan Health System among first in nation to use new device for stroke prevention

May 15, 2015

News Industry News

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

March 24, 2015

News Industry News

FDA Advisory Committee Panel Votes In Favor Of The WATCHMAN™ Left Atrial Appendage Closure Device

October 08, 2014

News Industry News

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

September 10, 2014

News Industry News

Boston Scientific Announces Schedule for Presentations at American College of Cardiology 2014

March 27, 2014

News Industry News

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

October 28, 2013

News Industry News

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

May 17, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

News Industry News

St. Jude Medical Receives CE Mark of Next-Generation Cardiac Device for Stroke Prevention

January 17, 2013

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

News Industry News

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

August 26, 2012

News Industry News

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

July 02, 2012

News Industry News

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR

May 16, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Industry News

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

November 15, 2011

News Industry News

Boston Scientific Announces Schedule of Events at TCT Scientific Symposium

November 01, 2011

News Industry News

Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN® Device

May 18, 2011

Advertisement

Good Samaritan Hospital Offers an Alternative to Long-Term Warfarin Medication for Atrial Fibrillation with Newly Approved Watchman™ LAAC Implant

University of Michigan Health System among first in nation to use new device for stroke prevention

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

FDA Advisory Committee Panel Votes In Favor Of The WATCHMAN™ Left Atrial Appendage Closure Device

Boston Scientific Announces Schedule For Presentations At Upcoming TCT 2014

Boston Scientific Announces Schedule for Presentations at American College of Cardiology 2014

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

St. Jude Medical Receives CE Mark of Next-Generation Cardiac Device for Stroke Prevention

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

Key Clinical Data for St. Jude Medical’s Structural Heart Technologies Revealed at EuroPCR

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

Boston Scientific Announces Schedule of Events at TCT Scientific Symposium

Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN® Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content